GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03364868|
Recruitment Status : Recruiting
First Posted : December 7, 2017
Last Update Posted : July 5, 2019
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 1||Drug: Oral Insulin Other: Placebo||Phase 2|
The GPPAD-POInT-Study aims to determine whether daily administration of oral insulin to children from age 4 months - 7 months with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies and diabetes in childhood. The purpose of the GPPAD-POInT-Study is to induce immune tolerance to beta-cell autoantigens through regular exposure to oral insulin for a period of 29 to 32 months. Together with the results of the currently ongoing Pre-POINT-Early Study, this phase IIb study aims to investigate and consolidate the findings from the pilot Pre-POINT Study, namely safety and immune efficacy at a daily dose of 67.5 mg oral insulin. Since babies and young children will be tested in the GPPAD-POInT-Study, the 67.5 mg dose will be reached by dose escalation starting at 7.5 mg for 2 months, followed by exposure to 22.5 mg for 2 months, and reaching the desired 67.5 mg dose. The GPPAD-POInT-Study aims to recruit 1040 children into the trial.
The active substance for oral application is human insulin. Oral Insulin will be applied as a capsule containing 7.5, 22.5 and 67.5 mg of the active substance together with filling substance microcrystalline cellulose.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1040 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Oral Insulin Therapy for Prevention of Autoimmune Diabetes|
|Actual Study Start Date :||February 7, 2018|
|Estimated Primary Completion Date :||January 2025|
|Estimated Study Completion Date :||January 2025|
Experimental: oral insulin capsule (dose escalation using 3 dose strengths)
Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
Drug: Oral Insulin
treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
Placebo Comparator: Placebo capsule
Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
- The development of persistent confirmed multiple beta-cell autoantibodies [ Time Frame: elapsed time from treatment assignment (baseline) to first positive sample visit (>2 beta-cell antibodies) in children who develop persistent confirmed multiple beta-cell antibodies. Primary outcome can develop any time up to last study visit at 7.5 yrs ]development of persistent confirmed multiple beta-cell autoantibodies (defined as confirmed IAA, confirmed GADA, confirmed IA-2A, or confirmed ZnT8A in two consecutive samples, AND a confirmed second antibody from these four antibodies in one sample.
- The development of diabetes [ Time Frame: elapsed time from random treatment assignment (baseline) to the development diabetes (date of diagnosis). This primary outcome measure can develop any time during treatment or follow-up period up to the last study visit at 7.5 years of age ]OGTT criteria or clinical criteria for diabetes as defined by the American Diabetes Association (ADA).
- Any persistent confirmed beta-cell autoantibody or diabetes [ Time Frame: elapsed time from treatm. assignm. (baseline) to 1st pos. sample for >1 beta-cell antibody in children who developed persist. confirm. beta-cell antibodies OR diabetes onset, whichever is first. outcome can develop any time up to last visit at 7.5 yr ]At least one confirmed autoantibody, in two consecutive samples, including GADA, IA-2A, IAA, ZnT8A, or TS7A, or diabetes as defined by the American Diabetes Association (ADA).
- Persistent confirmed IAA. [ Time Frame: elapsed time from treatment assignment (baseline) to first sample that is positive for IAA in children who develop persistent confirmed IAA. Outcome can develop any time during treatment or follow-up period up to the last study visit at 7.5 years of age. ]Confirmed IAA in two consecutive samples.
- Persistent confirmed GADA. [ Time Frame: elapsed time from treatment assignment (baseline) to the first sample that is positive for GADA in children who develop persistent confirmed GADA. Outcome can develop any time up to the last study visit at 7.5 years of age ]Confirmed GADA in two consecutive samples.
- Abnormal glucose tolerance (AGT) defined by dysglycemia or diabetes. [ Time Frame: elapsed time from treatment assignment to the date at which abnormal glucose tolerance or diabetes is diagnosed. Outcome can develop any time up to the last study visit at 7.5 years of age ]Dysglycemia is defined as impaired fasting plasma glucose of ≥110 mg/dL (6.1 mmol/L), or impaired 2-hour glucose of ≥140 mg/dL (7.8 mmol/L), or high glucose levels at intermediate time points on OGTT (30, 60, 90 min) levels of ≥200mg/dL (11.1 mmol/L)). Diabetes is defined according to the criteria of the American Diabetes Association (ADA).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364868
|Contact: Anette-G. Ziegler, Prof. Dr.||+49-(0)800 - 000 00 email@example.com|
|Contact: Peter Achenbach, PD Dr.||+49-(0)800 - 000 00 firstname.lastname@example.org|
|University Hospitals Leuven, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium||Recruiting|
|Leuven, Belgium, 3000|
|Contact: Kristina Casteels, Prof. Dr.|
|Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Munich, Germany||Recruiting|
|Munich, Bavaria, Germany, 80804|
|Contact: Anette-G. Ziegler, Prof. Dr. +49-(0)800 - 000 00 18 email@example.com|
|Contact: Peter Achenbach, Prof. Dr. +49-(0)800 - 000 00 18 firstname.lastname@example.org|
|AUF DER BULT, Kinder- und Jugendkrankenhaus, Hanover, Germany||Recruiting|
|Hanover, Lower Saxony, Germany, 30173|
|Contact: Olga Kordonouri, Prof. Dr.|
|Klinik und Poliklinik f. Kinder und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, CRTD/DFG-Forschungszentrum für Regenerative Therapien, Dresden, Germany||Recruiting|
|Dresden, Saxony, Germany, 01307|
|Contact: Reinhard Berner, Prof. Dr.|
|Medical University of Warsaw, Department of Paediatrics, Warsaw, Poland||Recruiting|
|Warsaw, Poland, 00-001|
|Contact: Agnieszka Szypowska, Prof. Dr.|
|Lund University Dep. of Clinical Sciences Malmo, Skane University Hospital SUS, University Hospital MAS, Malmo, Sweden||Recruiting|
|Malmö, Sweden, 202 13|
|Contact: Helena Elding Larsson, Assoc. Prof. Dr.|
|Department of Paediatrics Clinical Vaccine Research and Immunisation Education, Children's Hospital, Headington, Oxford, UK||Recruiting|
|Oxford, United Kingdom, OX3 9DU|
|Contact: Matthew Snape, Dr.|